Arecor and Medtronic announce diabetes collaboration

CAMBRIDGE, UK: Arecor Therapeutics plc, a trailblazer in biopharmaceuticals, has joined hands with healthcare technology titan Medtronic plc to forge a path in diabetes care with the development of a pioneering, high-concentration, thermostable insulin.

This cutting-edge insulin is set to be a cornerstone of Medtronic’s Diabetes sector, powering a revolutionary implantable pump designed to enhance patient well-being.

The collaboration promises to usher in a new era of insulin therapy, targeting a niche group of diabetes patients who find themselves constrained by the limitations of conventional treatments. The innovative insulin aims to reduce the frequency of pump maintenance, thereby broadening treatment options for physicians, enhancing patient care, and potentially reducing healthcare expenditures.

Sarah Howell, CEO of Arecor, expressed her enthusiasm for the partnership, highlighting Arecor’s proven expertise in ultra-rapid acting insulin development. “Our commitment to innovation is unwavering, and we’re poised to make significant strides in diabetes treatment with our unique insulin formulations, AT278 and AT247. The advent of advanced delivery devices is transforming patient care, and we’re at the forefront, driving progress with our distinctive insulin that promises to change the lives of those most in need,” Howell stated.

Echoing this sentiment, Gary Dulak, Senior Director at Medtronic Diabetes, shed light on the company’s pioneering efforts in implantable insulin pump systems, particularly for individuals with type 1 diabetes who struggle with subcutaneous insulin delivery. “Our collaboration with Arecor is a testament to our dedication to exploring innovative therapeutic avenues. The targeted intraperitoneal delivery via our implantable pump is a game-changer, ensuring efficient insulin absorption by the liver and marking a significant milestone in diabetes care,” Dulak remarked.

This strategic alliance is set to redefine diabetes management, particularly for those patients who stand to benefit most from this technological breakthrough.

Arecor Therapeutics and TRx Biosciences collaboration for oral diabetes treatment